Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells

Oncogene

Volumn 26, Issue 57, 2007, Pages 7904-7908

  Li, Q F ^a   Huang, W R ^b   Duan, H F ^a   Wang, H ^a   Wu, C T ^a   Wang, L S ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

BCR ABL; CML; Mcl 1; Sphingosine kinase 1

Indexed keywords

ADENOVIRUS VECTOR; IMATINIB; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; N,N DIMETHYLSPHINGOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1;

ANIMAL CELL; ARTICLE; BCR ABL GENE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NEOPLASM PROTEINS; NIH 3T3 CELLS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION;

ADENOVIRIDAE;

EID: 37149032222     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210587     Document Type: Article

References (22)

1. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311.
2. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen C. (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24: 178-187.
3. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T et al. (2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20: 95-102.
4. Cortez D, Stoica G, Pierce JH, Pendergast AM. (1996). The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13: 2589-2594.
5. Duan HF, Wu CT, Lu Y, Wang H, Liu HJ, Zhang QW et al. (2004). Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells. Exp Cell Res 298: 593-601.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
7. Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G et al. (2004). Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 18: 1456-1458.
8. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W et al. (2005). Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106: 1808-1816.
9. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA et al. 2005)). Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105: 3169-3177.
10. Lu ZZ, Ni F, Hu ZB, Wang L, Wang H, Zhang QW et al. (2006). Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp Hematol 34: 1170-1181.
11. Lugo TG, Pendergast AM, Muller AJ, Witte ON. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082.
12. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. (2005). Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307: 1101-1104.
13. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468-6472.
14. Sawyers CL. (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
15. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. (2000). STAT5 activation contributes to growth and viability in BCR/ABL-transformed cells. Blood 95: 2118-2125.
16. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt dependent pathway. EMBO J 16: 6151-6161.
17. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218.
18. Wattenberg BW, Pitson SM, Raben DM. (2006). The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J Lipid Res 47: 1128-1139.
19. Wu W, Mosteller RD, Broek D. (2004). Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 24: 7359-7369.
20. Xie S, Lin H, Sun T, Arlinghaus RB. (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21: 7137-7146.
21. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y. (1996). N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 35: 626-633.
22. Zhou P, Qian L, Kozopas KM, Craig RW. (1997). Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89: 630-643.